Gain Therapeutics (GANX) to Post Quarterly Earnings on Tuesday

Gain Therapeutics (NASDAQ:GANX) is anticipated to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Gain Therapeutics to announce earnings of ($0.14) per share and revenue of $0.0330 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Monday, May 11th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). During the same quarter in the previous year, the company earned ($0.16) earnings per share. On average, analysts expect Gain Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gain Therapeutics Stock Up 0.3%

Shares of Gain Therapeutics stock traded up $0.01 during trading on Tuesday, hitting $1.75. The company’s stock had a trading volume of 145,533 shares, compared to its average volume of 811,371. Gain Therapeutics has a 52 week low of $1.43 and a 52 week high of $4.34. The company has a market capitalization of $74.85 million, a PE ratio of -3.03 and a beta of 0.19. The company has a fifty day simple moving average of $1.79 and a two-hundred day simple moving average of $1.94. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.69 and a current ratio of 4.69.

Analyst Ratings Changes

A number of equities research analysts have weighed in on GANX shares. BTIG Research restated a “buy” rating and issued a $5.00 price objective on shares of Gain Therapeutics in a report on Tuesday, June 30th. Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Weiss Ratings cut Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Wednesday, July 1st. Finally, Wall Street Zen raised Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Gain Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

Institutional Investors Weigh In On Gain Therapeutics

Institutional investors have recently made changes to their positions in the company. Sprott Inc. bought a new stake in shares of Gain Therapeutics during the fourth quarter valued at approximately $39,000. Commonwealth Equity Services LLC bought a new position in Gain Therapeutics in the 4th quarter valued at approximately $41,000. Millennium Management LLC bought a new position in Gain Therapeutics in the 4th quarter valued at approximately $45,000. JPMorgan Chase & Co. bought a new position in Gain Therapeutics in the 3rd quarter valued at approximately $47,000. Finally, Engineers Gate Manager LP purchased a new stake in Gain Therapeutics during the 4th quarter valued at $47,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.